LFCR Valuation

Lifecore Biomedical Inc

Add to Watchlist

Advanced Chart

7.640

+0.27(3.664%)1D

LFCR Relative Valuation

LFCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LFCR is overvalued; if below, it's undervalued.

Historical Valuation

Lifecore Biomedical Inc (LFCR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -64.72. The fair price of Lifecore Biomedical Inc (LFCR) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：7.64

Fair

-9.10

Trailing

Forward

22.24

EV/EBITDA

Lifecore Biomedical Inc. (LFCR) has a current EV/EBITDA of 22.24. The 5-year average EV/EBITDA is 23.43. The thresholds are as follows: Strongly Undervalued below -13.78, Undervalued between -13.78 and 4.83, Fairly Valued between 42.04 and 4.83, Overvalued between 42.04 and 60.64, and Strongly Overvalued above 60.64. The current Forward EV/EBITDA of 22.24 falls within the Historic Trend Line -Fairly Valued range.

-81.09

EV/EBIT

Lifecore Biomedical Inc. (LFCR) has a current EV/EBIT of -81.09. The 5-year average EV/EBIT is -1.63. The thresholds are as follows: Strongly Undervalued below -172.06, Undervalued between -172.06 and -86.85, Fairly Valued between 83.59 and -86.85, Overvalued between 83.59 and 168.81, and Strongly Overvalued above 168.81. The current Forward EV/EBIT of -81.09 falls within the Historic Trend Line -Fairly Valued range.

2.12

Lifecore Biomedical Inc. (LFCR) has a current PS of 2.12. The 5-year average PS is 1.62. The thresholds are as follows: Strongly Undervalued below 0.67, Undervalued between 0.67 and 1.15, Fairly Valued between 2.10 and 1.15, Overvalued between 2.10 and 2.57, and Strongly Overvalued above 2.57. The current Forward PS of 2.12 falls within the Overvalued range.

21.08

P/OCF

Lifecore Biomedical Inc. (LFCR) has a current P/OCF of 21.08. The 5-year average P/OCF is 2.48. The thresholds are as follows: Strongly Undervalued below -13.05, Undervalued between -13.05 and -5.29, Fairly Valued between 10.24 and -5.29, Overvalued between 10.24 and 18.01, and Strongly Overvalued above 18.01. The current Forward P/OCF of 21.08 falls within the Strongly Overvalued range.

-32.69

P/FCF

Lifecore Biomedical Inc. (LFCR) has a current P/FCF of -32.69. The 5-year average P/FCF is -156.20. The thresholds are as follows: Strongly Undervalued below -2025.61, Undervalued between -2025.61 and -1090.91, Fairly Valued between 778.50 and -1090.91, Overvalued between 778.50 and 1713.21, and Strongly Overvalued above 1713.21. The current Forward P/FCF of -32.69 falls within the Historic Trend Line -Fairly Valued range.

Lifecore Biomedical Inc (LFCR) has a current Price-to-Book (P/B) ratio of 211.74. Compared to its 3-year average P/B ratio of 39.60 , the current P/B ratio is approximately 434.71% higher. Relative to its 5-year average P/B ratio of 24.47, the current P/B ratio is about 765.16% higher. Lifecore Biomedical Inc (LFCR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -13.82%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -12.37% , the current FCF yield is about -100.00% lower.

211.74

P/B

Median3y

39.60

Median5y

24.47

-4.93

FCF Yield

Median3y

-13.82

Median5y

-12.37

Competitors Valuation Multiple

The average P/S ratio for LFCR's competitors is 0.00, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 25.92%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LFCR.O

Lifecore Biomedical Inc

Relmada Therapeutics Inc

Loss

313.13M

FENC.O

Fennec Pharmaceuticals Inc

Avalo Therapeutics Inc

Aclaris Therapeutics Inc

Loss

-24.09%

271.95M

Performance Decomposition

Market capitalization of LFCR increased by 3.10% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -4.67 to -6.00.

The secondary factor is the Revenue Growth, contributed 25.92%to the performance.

Overall, the performance of LFCR in the past 1 year is driven by P/E Change. Which is more unsustainable.

25.92%

24.71M → 31.11M

Revenue Growth

-51.11%

-65.70 → -32.12

Margin Expansion

28.29%

-4.67 → -6.00

P/E Change

3.10%